Khomenko, TM, Zakharenko, AL, Chepanova, AA, Ilina, ES, Zakharova, OD, Kaledin, VI, Nikolin, VP, Popova, NA, Korchagina, DV, Reynisson, J, Chand, R, Ayine-Tora, DM, Patel, J, Leung, IKH, Volcho, KP, Salakhutdinov, NF and Lavrik, OI (2019) Promising New Inhibitors of Tyrosyl-DNA Phosphodiesterase I (Tdp 1) Combining 4-Arylcoumarin and Monoterpenoid Moieties as Components of Complex Antitumor Therapy. International Journal of Molecular Sciences, 21 (1). ISSN 1422-0067

[thumbnail of J. Reynisson Promising New Inhibitors.pdf]
J. Reynisson Promising New Inhibitors.pdf - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview


Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Herein, we report our work on the synthesis and characterization of new Tdp1 inhibitors that combine the arylcoumarin (neoflavonoid) and monoterpenoid moieties. Our results showed that they are potent Tdp1 inhibitors with IC50 values in the submicromolar range. In vivo experiments with mice revealed that compound 3ba (IC50 0.62 µM) induced a significant increase in the antitumor effect of topotecan on the Krebs-2 ascites tumor model. Our results further strengthen the argument that Tdp1 is a druggable target with the potential to be developed into a clinically-potent adjunct therapy in conjunction with Top1 poisons.

Item Type: Article
Uncontrolled Keywords: DNA repair enzymes, Tdp1 inhibitor, cancer, chemical space, coumarin, molecular modeling, neoflavone, topoisomerase 1 inhibitors, topotecan, tumor
Subjects: Q Science > QD Chemistry
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy
Related URLs:
Depositing User: Symplectic
Date Deposited: 07 Jan 2020 16:23
Last Modified: 03 Mar 2021 09:50

Actions (login required)

View Item
View Item